Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Döhner H1, Estey E2, Grimwade D3, Amadori S4, Appelbaum FR5, Büchner T6, Dombret H7, Ebert BL8, Fenaux P9, Larson RA10, Levine RL11, Lo-Coco F4, Naoe T12, Niederwieser D13, Ossenkoppele GJ14, Sanz M15, Sierra J16, Tallman MS11, Tien HF17, Wei AH18, Löwenberg B19, Bloomfield CD20.

Author information

Abstract

The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults published in 2010 has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease, as well as in the development of novel anti-leukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for a response category based on minimal residual disease status, and criteria for progressive disease.